The newly developed inhaled corticosteroid ciclesonide for the treatment of asthma

被引：14

作者：

Colice, Gene L.

机构：

[1] Washington Hosp Ctr, Pulm Serv, Washington, DC 20010 USA

[2] Washington Hosp Ctr, Crit Care Serv, Washington, DC 20010 USA

[3] Washington Hosp Ctr, Resp Serv, Washington, DC 20010 USA

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2006年 / 7卷 / 15期

关键词：

asthma; ciclesonide; inhaled corticosteroid;

D O I：

10.1517/14656566.7.15.2107

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Ciclesonide is the most recently developed inhaled corticosteroid for the treatment of asthma to enter global markets. It has been formulated as an aerosol solution in a metered dose inhaler with hydrofluoralkane. The mass median aerodynamic diameter of aerosolised ciclesonide is 1 - 2 mu m, providing excellent lung deposition characteristics. Ciclesonide can undergo reversible esterification in the lungs, possibly allowing once-daily dosing, and is highly protein bound, possibly leading to reduced systemic side effects. Clinical trials suggest that ciclesonide effectively controls asthma and has a favourable safety profile.

引用

收藏

页码：2107 / 2117

页数：11

相关论文

共 54 条

[21] Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma [J].

Kanniess, F ;

Richter, K ;

Böhme, S ;

Jörres, RA ;

Magnussen, H .

PULMONARY PHARMACOLOGY & THERAPEUTICS, 2001, 14 (02) :141-147

[22] A COMPARATIVE-STUDY OF THE EFFECTS OF AN INHALED CORTICOSTEROID, BUDESONIDE, AND A BETA-2-AGONIST, TERBUTALINE, ON AIRWAY INFLAMMATION IN NEWLY DIAGNOSED ASTHMA - A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP CONTROLLED TRIAL [J].

LAITINEN, LA ;

LAITINEN, A ;

HAAHTELA, T .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1992, 90 (01) :32-42

[23] Once-daily ciclesonide 80 or 320μg for 12 weeks is safe and effective in patients with persistent asthma [J].

Langdon, CG ;

Adler, M ;

Mehra, S ;

Alexander, M ;

Drollmann, A .

RESPIRATORY MEDICINE, 2005, 99 (10) :1275-1285

[24] Effect of ciclesonide on allergen challenge in subjects with bronchial asthma [J].

Larsen, BB ;

Nielsen, LP ;

Engelstätter, R ;

Steinijans, V ;

Dahl, R .

ALLERGY, 2003, 58 (03) :207-212

[25] Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma [J].

Lee, DKC ;

Fardon, TC ;

Bates, CE ;

Haggart, K ;

McFarlane, LC ;

Lipworth, BJ .

CHEST, 2005, 127 (03) :851-860

[26] Effects of hydrofluoroalkane formulations of ciclesonide 400 μg once daily vs fluticasone 250 μg twice daily on methacholine hyper-responsiveness in mild-to-moderate persistent asthma [J].

Lee, DKC ;

Haggart, K ;

Currie, GP ;

Bates, CE ;

Lipworth, BJ .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 (01) :26-33

[27] Effects of ciclesonide and fluticasone propionate on allergen-induced airway inflammation and remodeling features [J].

Leung, SY ;

Eynott, P ;

Nath, P ;

Chung, KF .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2005, 115 (05) :989-996

[28] Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma [J].

Lipworth, BJ ;

Kaliner, MA ;

LaForce, CF ;

Baker, JW ;

Kaiser, HB ;

Amin, D ;

Kundu, S ;

Williams, JE ;

Engelstaetter, R ;

Banerji, DD .

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2005, 94 (04) :465-472

[29] Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide [J].

Nave, R ;

Meyer, W ;

Fuhst, R ;

Zech, K .

PULMONARY PHARMACOLOGY & THERAPEUTICS, 2005, 18 (06) :390-396

[30]

Nave R, 2005, INT J CLIN PHARM TH, V43, P264

← 1 2 3 4 5 6 →